What is MMR Vaccine?
The MMR vaccine — short for Measles, Mumps, and Rubella vaccine — is one of the most widely administered childhood immunizations in the United States, and its significance in 2026 has never been more urgent. Developed to protect against three highly contagious viral diseases, the MMR vaccine works by introducing a live-attenuated (weakened) version of the viruses into the body, training the immune system to recognize and fight off future infections. In the United States, the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP) recommend that children receive their first MMR dose between 12 to 15 months of age and their second dose between 4 to 6 years of age. When both doses are completed on schedule, the vaccine provides long-lasting and, in most cases, lifelong protection against all three diseases.
As of April 2026, the MMR vaccine sits at the center of one of the most serious public health crises the United States has faced in decades. After measles was declared eliminated from the U.S. in the year 2000, a slow but persistent decline in vaccination coverage — accelerated by the COVID-19 pandemic and rising vaccine hesitancy — has reversed decades of progress. What was once a success story of modern medicine is now being stress-tested in real time, with measles cases in 2026 already surpassing 1,748 confirmed infections as of April 16, 2026, according to CDC data. Understanding the latest MMR vaccine statistics 2026, coverage rates, exemption trends, and hesitancy patterns is not just a public health exercise — it is a necessary step toward protecting communities across America.
Interesting Facts About the MMR Vaccine in the US 2026
Before diving into the numbers, here are the most compelling and critical facts about the MMR vaccine in the United States as of 2026. These facts — sourced exclusively from U.S. government and peer-reviewed scientific sources — paint a vivid picture of where America stands right now.
| Fact | Detail |
|---|---|
| MMR vaccine effectiveness (2 doses, measles) | 97% effective at preventing measles |
| MMR vaccine effectiveness (1 dose, measles) | 93% effective at preventing measles |
| MMR vaccine effectiveness (mumps, 2 doses) | 88% effective at preventing mumps |
| MMR vaccine effectiveness (rubella, 1 dose) | 97% effective at preventing rubella |
| Herd immunity threshold for measles | Requires ≥95% community vaccination to prevent outbreak spread |
| U.S. kindergarten MMR coverage (2024–2025) | Only 92.5% — below the 95% herd immunity threshold |
| U.S. kindergarten MMR coverage (2019–2020) | Was 95.2% — above the herd immunity threshold |
| Kindergartners without full MMR documentation (2024–25) | Approximately 286,000 kindergartners unprotected |
| Measles cases confirmed in U.S. — full year 2025 | 2,288 confirmed cases — the highest in over 3 decades |
| Measles cases confirmed in U.S. — 2026 (as of April 16) | 1,748 confirmed cases across 33 jurisdictions |
| Percentage of 2026 cases in unvaccinated individuals | 94% of confirmed cases were unvaccinated or unknown status |
| First MMR dose schedule (ACIP recommendation) | 12 to 15 months of age |
| Second MMR dose schedule (ACIP recommendation) | 4 to 6 years of age |
| Measles eliminated in U.S. | Year 2000 — now under serious threat of losing elimination status |
| States below 95% MMR coverage (2024–25) | 39 states — up from 28 states before the pandemic |
| States below 90% MMR coverage (2024–25) | 16 states — up from only 3 states in 2019–2020 |
| Highest MMR coverage state (2024–25) | Connecticut — 98.2% |
| Lowest MMR coverage state (2024–25) | Idaho — 78.5% |
| Kindergarten vaccine exemption rate (2024–25) | 3.6% — an all-time recorded high |
| Number of kindergartners with exemptions (2024–25) | Approximately 138,000 kindergartners |
| States with exemption rates above 5% (2024–25) | 17 states — up from 9 states pre-pandemic |
| Highest exemption rate state (2024–25) | Idaho — 15.4% |
| Share of 2025 U.S. measles cases in under-5-year-olds | Nearly 30% of all cases — highest hospitalization group |
| Hospitalization rate of under-12-month infants (2025) | 18% of that age group required hospitalization |
| Adults who heard the false MMR-autism claim (KFF poll, April 2025) | 63% of U.S. adults had heard or read this debunked claim |
Data Sources: CDC SchoolVaxView, CDC Measles Cases and Outbreaks, CDC Measles Vaccine Recommendations, NCBI StatPearls, KFF Health Tracking Poll, ACIP
The facts above tell a story that deserves careful attention. The MMR vaccine remains one of the most effective vaccines ever developed, with a 97% efficacy rate for measles prevention after two doses — yet the United States is experiencing measles surges that mirror patterns from the pre-vaccine era. The drop in kindergarten MMR coverage from 95.2% in 2019–2020 to just 92.5% in 2024–2025 may look small in percentage terms, but in real numbers, it translates to an additional 286,000 unprotected kindergartners each year. More alarming is the geographic concentration of the problem — with 39 states now falling below the critical 95% herd immunity threshold, pockets of vulnerability are no longer rare outliers but a national pattern. The gap between the best-performing state (Connecticut at 98.2%) and the worst (Idaho at 78.5%) is nearly 20 percentage points, making clear that the problem is not evenly distributed.
What makes the current situation especially sobering is the speed of the escalation. In 2025 alone, the U.S. recorded 2,288 confirmed measles cases — the most in more than 33 years — and 2026 is already tracking worse, with 1,748 confirmed cases by April 16, 2026. Among all confirmed 2026 cases, 94% involve unvaccinated individuals or those with unknown vaccine status, making it unmistakable that the MMR vaccine, when received, works as intended. The 63% of American adults who have encountered the false autism claim about the MMR vaccine underscores why accurate, verified data on MMR vaccine statistics 2026 must be widely available and clearly communicated.
National MMR Vaccine Coverage Rates in the US 2026
The national picture for MMR vaccination coverage reflects a multi-year decline that has now clearly crossed into crisis territory. The following data represents the most recent verified statistics from the CDC’s SchoolVaxView reporting system.
| School Year | National MMR Coverage (Kindergartners) | Change from Prior Year | States Below 95% |
|---|---|---|---|
| 2019–2020 | 95.2% | Baseline (pre-pandemic) | 28 states |
| 2020–2021 | ~93.0% | ↓ ~2.2 pp | — |
| 2021–2022 | ~93.0% | Essentially unchanged | — |
| 2022–2023 | ~93.0% | Essentially unchanged | — |
| 2023–2024 | 92.7% | ↓ 0.3 pp | 36+ states |
| 2024–2025 | 92.5% | ↓ 0.2 pp | 39 states |
Data Source: CDC SchoolVaxView — Vaccination Coverage and Exemptions Among Kindergartners, 2024–2025 School Year
The national MMR vaccination rate of 92.5% in the 2024–2025 school year is not simply a statistic — it is a threshold breach. The 95% herd immunity benchmark represents the level at which measles cannot sustain community transmission; fall below it, and the virus finds enough susceptible hosts to spread. For five consecutive school years, the United States has failed to meet this benchmark. The decline from 95.2% in 2019–2020 to 92.5% in 2024–2025 translates to a population-level risk that the current surge of measles cases is now making terrifyingly concrete. What is particularly troubling is that coverage with MMR, DTaP, polio, and varicella vaccines all declined simultaneously in more than half of states during the 2024–2025 school year, signaling a broad systemic erosion rather than a problem confined to a single vaccine type.
The fact that 39 out of 50 states now fall below the 95% MMR coverage threshold — compared to just 28 states before the pandemic — reflects how COVID-19 disrupted childhood immunization schedules at a scale that has yet to be corrected. Families that skipped or delayed vaccines during lockdowns in 2020 and 2021 did not simply resume where they left off, and many communities never recovered their pre-pandemic vaccination habits. Public health officials have repeatedly warned that the window to correct this trend without catastrophic disease resurgence is closing rapidly.
State-by-State MMR Vaccine Coverage in the US 2026
Geographic variation in MMR vaccine coverage across American states is among the most important factors driving the current measles outbreak situation. The data below, sourced from CDC’s most recent SchoolVaxView reporting for the 2024–2025 school year, highlights the extremes of this variation.
| State | MMR Coverage (2024–25) | Status vs. 95% Threshold |
|---|---|---|
| Connecticut | 98.2% | ✅ Above threshold |
| Mississippi | ~97%+ | ✅ Above threshold |
| Rhode Island | ~96%+ | ✅ Above threshold |
| New York | ~96%+ | ✅ Above threshold |
| Arkansas | ~96%+ | ✅ Above threshold |
| National Average | 92.5% | ❌ Below threshold |
| Florida | ~88.1% | ❌ Below threshold |
| Colorado | ~88.3% | ❌ Below threshold |
| Oklahoma | ~88.3% | ❌ Below threshold |
| Utah | ~88.8% | ❌ Below threshold |
| Wisconsin | ~84.8% | ❌ Well below threshold |
| Alaska | ~84.3% | ❌ Well below threshold |
| Idaho | 78.5% | ❌ Critically below threshold |
Data Source: CDC SchoolVaxView — 2024–2025 School Year; KFF Analysis of CDC Data
The spread of MMR coverage rates across U.S. states in the 2024–2025 school year is nearly 20 percentage points wide, from Connecticut’s 98.2% down to Idaho’s 78.5%. This is not merely a policy concern — it is an epidemiological fault line. States like Idaho, Alaska, and Wisconsin, all sitting well below the 90% MMR coverage level, represent concentrated pockets of measles vulnerability where a single imported case can ignite a community outbreak, as 2025’s catastrophic Texas outbreak demonstrated. The 16 states that now fall below 90% MMR coverage represents a staggering increase from just 3 states during the pre-pandemic 2019–2020 school year.
High-performing states like Connecticut, Mississippi, Rhode Island, and New York demonstrate that reaching and maintaining the 95% MMR coverage threshold is entirely achievable within the existing U.S. immunization infrastructure. The problem is political will, public trust, and consistent outreach — not vaccine availability or cost. The gap between top and bottom performers has grown wider over the past five years, reflecting diverging state-level policies, exemption laws, and public health communication strategies. Until the bottom-performing states close this gap, the national MMR vaccination rate will remain insufficient to prevent endemic measles re-establishment.
MMR Vaccine Exemption Rates in the US 2026
Vaccine exemptions — both medical and non-medical — have reached levels that directly undermine the effectiveness of the U.S. MMR vaccination program. The following data reflects the CDC’s most recent reporting for the 2024–2025 school year.
| Metric | 2019–2020 (Pre-Pandemic) | 2023–2024 | 2024–2025 |
|---|---|---|---|
| National exemption rate (one or more vaccines) | 2.5% | 3.3% | 3.6% (all-time high) |
| Non-medical exemption rate | 2.2% | ~3.0% | 3.4% |
| Number of exempt kindergartners | ~95,000 | ~133,000 | ~138,000 |
| States with exemption rates above 5% | 9 states | 14 states | 17 states |
| Highest exemption rate state | — | — | Idaho — 15.4% |
| States where ≥5% exemptions make 95% coverage mathematically impossible | 2 states | 14 states | 17 states |
Data Source: CDC SchoolVaxView — Vaccination Coverage and Exemptions Among Kindergartners, 2024–2025 School Year
The rise in vaccine exemption rates is perhaps the most structurally dangerous trend in MMR vaccine statistics 2026 because it represents a policy-enabled pathway around immunization requirements that grows harder to reverse over time. The 3.6% national kindergarten exemption rate in 2024–2025 is an all-time recorded high, and the nearly 138,000 kindergartners it represents are not uniformly distributed — they cluster in communities where vaccine hesitancy and permissive exemption laws converge, creating the precise conditions for outbreak ignition. Idaho’s exemption rate of 15.4% is not an outlier to be dismissed; it is a warning sign, and its combination with the state’s 78.5% MMR coverage rate makes it one of the most measles-vulnerable jurisdictions in the entire country.
The 17 states where exemption rates exceed 5% have crossed a particularly critical threshold: even if every single non-exempt kindergartner in those states were fully vaccinated, the 95% herd immunity level for MMR would still be mathematically unreachable. This was true of only 2 states in 2020–2021, making the jump to 17 states in just five years a fundamental shift in the public health landscape. The vast majority of this increase is driven by non-medical exemptions — meaning philosophical or religious objections — not legitimate medical contraindications, underlining that exemption policies and public messaging are core levers for reversing this trend.
Measles Outbreak Data Linked to MMR Under-Vaccination in the US 2026
The real-world consequences of declining MMR vaccination rates are now fully visible in CDC-confirmed measles case data. The following table presents the most current outbreak statistics verified from the CDC’s official Measles Cases and Outbreaks data tracker.
| Year | Confirmed U.S. Measles Cases | Key Notes |
|---|---|---|
| 2019 | 1,274 | Previous post-elimination record high |
| 2020 | ~13 | COVID reduced transmission opportunities |
| 2021 | ~49 | Pandemic suppression continued |
| 2022 | ~121 | Cases began rising again |
| 2023 | ~59 | Isolated outbreaks |
| 2024 | ~285 | Continued climb |
| 2025 | 2,288 | Highest in 33+ years; 3 deaths |
| 2026 (as of April 16) | 1,748 | Across 33 jurisdictions; 19 new outbreaks |
Data Source: CDC Measles Cases and Outbreaks, April 16, 2026 update
The measles case trajectory in the United States is no longer a warning of what might happen if MMR coverage continues to fall — it is the reality of what is already happening. 2025’s total of 2,288 confirmed measles cases shattered the previous post-elimination record of 1,274 cases set in 2019, and included 3 measles-related deaths, the first since 2015. Going into 2026, the pace has not meaningfully slowed: 1,748 confirmed cases as of April 16, 2026, spread across 33 states and jurisdictions, with 19 distinct outbreaks active or recently concluded. Of all confirmed 2026 cases, 94% involve unvaccinated individuals or those with unknown vaccination status — an unmistakable statistical confirmation that the MMR vaccine works and that the outbreak is a direct consequence of coverage gaps.
The geographic epicenter has shifted over time: the devastating 2025 West Texas outbreak — where some counties had kindergarten MMR coverage below 70% — gave way to a major 2025–2026 outbreak in South Carolina, with over 973 cases from a single chain of transmission that began in the fall of 2025. With 21% of 2026 cases involving children under five years old and 73% in individuals under age 19, the burden of this entirely preventable disease is falling disproportionately on the youngest and most vulnerable Americans.
MMR Vaccine Hesitancy Statistics in the US 2026
Vaccine hesitancy — defined as reluctance or refusal to vaccinate despite the availability of vaccines — is widely recognized as the primary behavioral driver behind declining MMR coverage rates in the United States. The data below captures the scope and nature of MMR vaccine hesitancy as measured by government and peer-reviewed research.
| Hesitancy Metric | Statistic | Source / Year |
|---|---|---|
| U.S. adults who heard the false MMR-autism claim | 63% | KFF Health Tracking Poll, April 2025 |
| U.S. adults who say vaccines approved in the U.S. are safe | 70% | Annenberg Public Policy Center, 2025 |
| Prior belief (2021–2022) that approved vaccines are safe | 76–79% | APPC Surveys |
| Non-medical exemptions, share of all exemptions (2024–25) | Vast majority — ~3.4% of kindergartners | CDC SchoolVaxView |
| Exemption rate increase since 2020–2021 | From 2.5% to 3.6% — a 44% relative increase | CDC SchoolVaxView |
| Counties below herd immunity threshold for MMR | 5.2 million kindergarten-age children in such counties | Washington Post / CDC data |
| Children 13.1% susceptible to measles (modeled estimate) | Under-18 population with measles susceptibility | Peer-reviewed modeling, published 2022 |
| Share of 2026 measles cases — unvaccinated or unknown status | 94% | CDC, April 2026 |
Data Sources: KFF Health Tracking Poll April 2025; Annenberg Public Policy Center Survey 2025; CDC SchoolVaxView; CDC Measles Cases and Outbreaks; CIDRAP reporting
Vaccine hesitancy in the context of the MMR vaccine in 2026 is not a monolithic phenomenon — it is shaped by a layered mix of misinformation, distrust of institutions, political polarization, and pandemic-era disruptions that created fertile ground for doubt. The single most persistent piece of misinformation driving MMR vaccine hesitancy remains the debunked 1998 claim linking the vaccine to autism — a study that was retracted, its author stripped of his medical license, and its findings conclusively refuted by dozens of large-scale studies. Yet 63% of U.S. adults as of April 2025 reported having encountered this false claim, illustrating the remarkable staying power of vaccine misinformation in the digital information environment. The parallel drop in Americans who believe approved vaccines are safe — from 76–79% in 2021–2022 down to 70% in 2025 — reflects how institutional trust has eroded even during a period when vaccine efficacy data has only grown stronger.
The real-world consequence of widespread MMR hesitancy is visible in both exemption trends and outbreak data. The 44% relative increase in kindergarten vaccine exemption rates between 2020–2021 and 2024–2025 — from 2.5% to 3.6% — tracks closely with measurable increases in social media misinformation consumption, COVID vaccine controversy spillover, and the normalization of “personal choice” framing around childhood immunizations. With 5.2 million kindergarten-age children now living in counties where MMR coverage falls below the herd immunity threshold, the structural risk embedded in current hesitancy patterns extends far beyond the families who choose not to vaccinate — it creates exposure risk for immunocompromised individuals, infants too young to be vaccinated, and anyone whose vaccine-induced immunity has waned.
MMR Vaccine Dose Schedule & Demographic Reach in the US 2026
Understanding who receives the MMR vaccine, when, and across which demographic groups provides essential context for interpreting coverage gaps and targeting interventions.
| Population Group | Recommended Dose / Schedule | Coverage Notes |
|---|---|---|
| Infants (standard schedule) | Dose 1: 12–15 months | Delay in first dose linked to outbreak vulnerability |
| Children (standard schedule) | Dose 2: 4–6 years | Second dose provides catch-up for non-responders |
| Infants in outbreak areas | Early dose: 6–11 months (emergency guidance) | Recommended by CDC/local health depts during outbreaks |
| Unvaccinated children (catch-up) | 2 doses, 28+ days apart | ACIP official recommendation |
| High-risk adults | 2 documented doses | Healthcare workers, college students, intl. travelers |
| International travelers (U.S.-based) | Evidence of 2 MMR doses required | CDC travel advisory standing recommendation |
| Immunocompromised individuals | MMR contraindicated | Rely on herd immunity for protection |
| Adults vaccinated before 1968 (inactivated vaccine) | At least 1 live MMR dose | Old killed vaccine was not effective |
| Pregnant women | Do not receive during pregnancy | Vaccinate after delivery; rubella protection critical |
| Post-exposure prophylaxis | MMR within 72 hours of exposure | Can prevent or modify disease course |
Data Source: CDC Measles Vaccine Recommendations; ACIP Guidelines; CDC Measles Vaccination Page (updated May–December 2025)
The MMR vaccine dosing schedule in the United States is one of the most clearly evidence-based immunization protocols in existence, yet even small disruptions in its delivery create compounding vulnerability over time. The standard two-dose schedule — first dose at 12–15 months, second at 4–6 years — is designed to ensure that the roughly 5% of children who do not develop full immunity from the first dose receive a second opportunity before school entry. When coverage falls below 95% at kindergarten age, as it has for five consecutive years, that small non-immune fraction grows large enough in aggregate to sustain measles transmission chains. The 2025 and 2026 outbreaks have additionally prompted local health departments to recommend early emergency MMR doses for infants as young as 6 months in outbreak-affected areas — an unusual measure reserved for crisis situations.
The high-risk adult categories defined by ACIP — including healthcare workers, college students, and international travelers — represent populations where MMR vaccine documentation is especially critical, given the potential for these groups to encounter imported measles and transmit it to vulnerable community members. The 10 travel-associated cases among international visitors to the U.S. already confirmed in 2026 as of April 16 illustrate how quickly globally-imported measles can seed domestic transmission when sufficient unvaccinated populations exist. For immunocompromised individuals — who cannot safely receive the live-attenuated MMR vaccine — the entire burden of protection rests on the herd immunity that a sufficiently vaccinated surrounding community provides. At 92.5% national coverage, that protection is no longer reliably in place.
MMR Vaccine Safety Profile in the US 2026
The safety record of the MMR vaccine is one of the most extensively studied in the history of modern medicine. Government agencies, independent researchers, and international health bodies have consistently affirmed its favorable risk-benefit profile.
| Side Effect / Safety Metric | Frequency / Risk Level | Source |
|---|---|---|
| Sore arm / injection site soreness | Common — mild, short-lived | CDC |
| Mild fever post-vaccination | Common — typically resolves within days | CDC |
| Mild rash (non-contagious) | Occurs in some recipients within 3 weeks | CDC |
| Joint pain / stiffness | Possible, especially in adult women | CDC |
| Febrile seizure (1st dose, MMRV vs. MMR) | ~1 in 2,300–2,600 children (MMRV first dose) | CDC ACIP Briefing, Sept. 2025 |
| Aseptic meningitis | Associated only with Urabe/Leningrad-Zagreb strains — NOT Jeryl Lynn strain used in U.S. | NCBI/Cochrane Review 2025 |
| MMR-autism link | No evidence. Conclusively debunked. | CDC; NIH; WHO; AAP |
| Deaths attributable to MMR in healthy individuals | None confirmed | IDSA |
| Serious adverse events in healthy recipients | Extremely rare | CDC; ACIP |
Data Sources: CDC Measles Vaccination Page; ACIP September 2025 Briefing Document; NCBI StatPearls (updated May 2025); IDSA Measles Facts Page (2026)
The safety profile of the MMR vaccine in 2026 remains exactly what decades of post-licensure surveillance have consistently shown: mild, short-lived side effects are common; serious adverse events are extremely rare; and no confirmed deaths attributable to the MMR vaccine in healthy individuals have ever been documented, according to the Infectious Diseases Society of America. The most common reactions — sore arm, mild fever, and occasional rash — are signs of the immune system responding appropriately and resolve without intervention within days to weeks. The single most damaging piece of misinformation about MMR vaccine safety — the alleged autism link — originated in a 1998 study that was formally retracted, whose lead author was stripped of his medical license for ethical violations, and which has been conclusively refuted by numerous large-scale studies involving millions of children worldwide.
It is important to distinguish between strains when discussing the rare risk of aseptic meningitis: this association exists only with the Urabe and Leningrad-Zagreb mumps strains, neither of which is used in the United States. The American MMR vaccine uses the Jeryl Lynn mumps strain, for which no such association has been found. The 2025 ACIP briefing document on MMRV vaccines confirmed that no new or unexpected safety signals were detected from ongoing post-licensure surveillance, reinforcing the favorable safety profile of the vaccine as currently formulated and administered. For any American weighing the risks and benefits of the MMR vaccine, the evidence is unambiguous: the risks of measles, mumps, and rubella infections — including encephalitis, pneumonia, deafness, birth defects in unborn children, and death — far exceed the negligible risks of the vaccine itself.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
